摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(furan-2-yl)-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine | 1138241-17-4

中文名称
——
中文别名
——
英文名称
4-(furan-2-yl)-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine
英文别名
(2R,3R,4S,5R)-2-[4-(furan-2-yl)imidazo[4,5-c]pyridin-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol
4-(furan-2-yl)-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine化学式
CAS
1138241-17-4
化学式
C15H15N3O5
mdl
——
分子量
317.301
InChiKey
QWTJPSKMXRGJBQ-JUDXGUMMSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.5
  • 重原子数:
    23
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    114
  • 氢给体数:
    3
  • 氢受体数:
    7

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
    —— 4-Chlor-1-β-D-ribofuranosyl-1H-imidazo<4,5-c>pyridin 6736-60-3 C11H12ClN3O4 285.687

反应信息

  • 作为产物:
    描述:
    2-呋喃硼酸4-Chlor-1-β-D-ribofuranosyl-1H-imidazo<4,5-c>pyridin 在 tri(3-sulfonatophenyl)phosphine trisodium salt 、 palladium diacetate 、 sodium carbonate 作用下, 以 乙腈 为溶剂, 反应 3.0h, 以88%的产率得到4-(furan-2-yl)-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine
    参考文献:
    名称:
    Cytostatic and Antiviral 6-Arylpurine Ribonucleosides IX. Synthesis and Evaluation of 6-Substituted 3-Deazapurine Ribonucleosides
    摘要:
    一系列带有不同C-取代基(烷基,芳基和杂环芳基)的3-去氮嘌呤核苷类化合物5a-5l在6位经过Pd催化的交叉偶联反应中由自由的6-氯-3-去氮嘌呤核苷类化合物4或其乙酰保护的同分异构体3制备而成,随后去保护基。通过使用硅基核苷碱与1,2,3,5-四-O-乙酰-β-D-核糖苷(2)进行Vorbrüggen糖基化反应,改进了起始化合物4-氯-1-(2,3,5-三-O-乙酰-β-D-核糖呋喃基)-1H-咪唑[4,5-c]吡啶(3)的合成方法。化合物5a-5l均未表现出任何显著的细胞毒或抗病毒活性。
    DOI:
    10.1135/cccc20080665
点击查看最新优质反应信息

文献信息

  • Cytostatic and Antiviral 6-Arylpurine Ribonucleosides IX. Synthesis and Evaluation of 6-Substituted 3-Deazapurine Ribonucleosides
    作者:Petr Nauš、Martin Kuchař、Michal Hocek
    DOI:10.1135/cccc20080665
    日期:——

    A series of 3-deazapurine ribonucleosides 5a-5l bearing diverse C-substituents (alkyl, aryl and heteroaryl) in the position 6 were prepared by Pd-catalyzed cross-coupling reactions of either free 6-chloro-3-deazapurine ribonucleoside 4 or its acetyl protected congener 3 followed by deprotection. An improved synthesis of the starting 4-chloro-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine (3) was developed by the application of Vorbrüggen glycosylation of silylated nucleobase with 1,2,3,5-tetra-O-acetyl-β-D-ribofuranose (2). None of compounds 5a-5l showed any considerable cytostatic or antiviral activity.

    一系列带有不同C-取代基(烷基,芳基和杂环芳基)的3-去氮嘌呤核苷类化合物5a-5l在6位经过Pd催化的交叉偶联反应中由自由的6-氯-3-去氮嘌呤核苷类化合物4或其乙酰保护的同分异构体3制备而成,随后去保护基。通过使用硅基核苷碱与1,2,3,5-四-O-乙酰-β-D-核糖苷(2)进行Vorbrüggen糖基化反应,改进了起始化合物4-氯-1-(2,3,5-三-O-乙酰-β-D-核糖呋喃基)-1H-咪唑[4,5-c]吡啶(3)的合成方法。化合物5a-5l均未表现出任何显著的细胞毒或抗病毒活性。
查看更多

同类化合物

4-氨基-1-(2’,3’,5’-三-O-叔-丁基二甲基硅烷基-beta-D-呋喃核糖基)-咪唑并[4,5-a]吡啶 3-脱氮腺苷 3-去氮杂鸟苷酸 3-去氮杂鸟苷三磷酸酯 3-去氮杂鸟苷 1-(2-脱氧-beta-D-赤式-呋喃戊糖基)-1H-咪唑并[4,5-c]吡啶-4-胺 1-(2,3,5-三-O-乙酰基-beta-D-呋喃核糖基)-4,6-二氯咪唑并[4,5-c]吡啶 5'-O-(N-L-seryl)sulfamoyl-3-deaza-adenosine 5'-O-(N-glycyl)sulfamoyl-3-deaza-adenosine 5'-O-(N-L-isoleucyl)sulfamoyl-3-deaza-adenosine 2-Fluoro-3-deaza-adenosine 4-(pyridin-3-yl)-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine 4-(pyrrol-3-yl)-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine 4-(pyrrol-2-yl)-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine 4-(furan-2-yl)-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine 1-(β-D-ribofuranosyl)-4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridine 4-cyclopropyl-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine 4-methyl-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine 1-(β-D-ribofuranosyl)-4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridine Adenosine, 3-deaza- (2R,3S,5R)-5-(4-Dimethylamino-imidazo[4,5-c]pyridin-1-yl)-2-hydroxymethyl-tetrahydro-furan-3-ol (2R,3S,5R)-2-Hydroxymethyl-5-(4-mercapto-imidazo[4,5-c]pyridin-1-yl)-tetrahydro-furan-3-ol 4-chloro-7-fluoro-1-(2'-C-methyl-β-D-ribofuranosyl)-imidazo[4,5-c]pyridine 4-ethyl-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine (2R,3S,5R)-5-(4-Benzylamino-imidazo[4,5-c]pyridin-1-yl)-2-hydroxymethyl-tetrahydro-furan-3-ol 4-(Methylsulfanyl)-1-pentofuranosyl-1H-imidazo[4,5-c]pyridine 4,7-difluoro-1-(2,3,5-tri-O-benzoyl-2-C-methyl-β-D-ribofuranosyl)-imidazo[4,5-c]pyridine 6-Chloro-n,n-dimethyl-1-pentofuranosyl-1h-imidazo[4,5-c]pyridin-4-amine 2-(6-Chloro-4-methoxyimidazo[4,5-c]pyridin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol 2-(4-Benzylsulfanyl-6-chloroimidazo[4,5-c]pyridin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol 2-(6-Chloro-4-methylsulfanylimidazo[4,5-c]pyridin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol N-[4-bromo-1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]imidazo[4,5-c]pyridin-6-yl]acetamide 5,6-Diamino-1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]imidazo[4,5-c]pyridin-4-one 1-amino-3-deazaguanosine 3-deazainosine 6-chloro-4-(cyclohexylamino)-1-(3-deoxy-β-D-ribofuranosyl)-1H-imidazo<4,5-c>pyridine [(2R,3R,4R,5R)-3,4-dibenzoyloxy-5-(4,6-dichloroimidazo[4,5-c]pyridin-1-yl)-4-methyloxolan-2-yl]methyl benzoate 4-amino-6-chloro-1-(3-deoxy-β-D-ribofuranosyl)-1H-imidazo<4,5-c>pyridine 4-amino-1-(2-deoxy-b-d-ribofuranosyl)-7-(1-naphthylethynyl)-imidazo[4,5-c]pyridine 3-Deazaguanosine 3',5'-cyclic phosphate 4-chloro-7-fluoro-1-(β-D-ribofuranosyl)imidazo[4,5-c]pyridine (2R,3S,5R)-5-(4-Benzylsulfanyl-imidazo[4,5-c]pyridin-1-yl)-2-hydroxymethyl-tetrahydro-furan-3-ol 4-(1H-pyrazol-5-yl)-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine 2-bromo-5-methyl-1-(2,3,5-tri-O-t-butyldimethyl-silyl-β-D-ribofuranosyl)imidazo[4,5-c]pyridin-4(5H)-one 4-amino-6-fluoro-1-(2,3,5-tri-O-benzyl-β-D-arabinofuranosyl)imidazo[4,5-c]pyridine 4-amino-6-fluoro-1-(2,3,5-tri-O-benzyl-α-D-arabinofuranosyl)imidazo[4,5-c]pyridine 4-chloro-1-(2',3'-dideoxy-α-D-glycero-pentofuranosyl)-1H-imidazo<4,5-c>pyridine 4-chloro-1-(2',3'-dideoxy-5'-O-<(1'',1 ''-dimethylethyl)dimethylsilyl>-β-D-glycero-pentofuranosyl)-1H-imidazo<4,5-c>pyridine 4-chloro-1-(2',3'-dideoxy-5'-O-<(1'',1 ''-dimethylethyl)dimethylsilyl>-α-D-glycero-pentofuranosyl)-1H-imidazo<4,5-c>pyridine 4-(furan-3-yl)-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine